UltraGreen.ai Limited, a leader in fluorescence-guided surgery, has announced the successful balloting results of its Singapore Public Offer, which closed on 1 December 2025. The IPO attracted significant interest, being oversubscribed 13.6 times, and raised approximately $400m, including $237.5m in cornerstone commitments from 16 investors.
The company is set to list on the SGX Mainboard on 3 December 2025 under the stock code ULG. The funds will be used to invest in core products such as the IC-Flow™ Imaging System and the UltraGreen Data Platform, as well as for strategic expansion across Asia-Pacific, Europe, the Middle East, and Africa.
UltraGreen’s CEO, Ravinder Sajwan, expressed gratitude for the investor support, stating, “This response reflects growing recognition of how fluorescence-guided surgery is transforming surgical precision, and UltraGreen’s role at the forefront of that movement.”
The company is advancing towards launching its UltraGreen Data Platform, which includes AI-based PerfusionWorks software designed to enhance decision-making in surgeries. Chairman Kwa Chong Seng highlighted the investor confidence in UltraGreen’s scientific and commercial capabilities, emphasising the company’s commitment to innovation and global expansion.
Trading of UltraGreen’s shares will commence at 9.00 a.m. on 3 December 2025, marking a significant milestone for the company as it continues to expand its influence in the medical technology sector.
